🇮🇱Ministry of Health Israel

MOH Israel NAMs Framework

Israel's MOH enables a strong biotech ecosystem with FDA-harmonized pathways for NAMs acceptance, supporting the Startup Nation's innovation.

FDA
Aligned
Startup
Nation
2024
Policy
3Rs
Support
Written by J Radler | Patient Analog
Last updated: January 2025

Regulatory Highlights

  • Current regulatory framework and acceptance pathways
  • Compliance requirements for NAMs submissions
  • International harmonization through ICH guidelines
  • Practical guidance for regulatory strategy

Israel's Biotech Innovation

Israel's "Startup Nation" reputation extends to biotechnology, with numerous organ-on-chip and organoid companies emerging from its strong research ecosystem.

FDA-Harmonized Approach

MOH Israel closely aligns with FDA regulatory standards:

  • Reference Approval: FDA-approved NAMs recognized with documentation
  • Innovation Pathway: Expedited review for breakthrough technologies
  • Scientific Advice: Pre-submission meetings available

Israeli NAMs Companies

  • Quris-AI: AI-powered clinical prediction platform
  • Tissue Dynamics: Organ-on-chip systems
  • Weizmann Institute: Leading organoid research